Published in J Clin Invest on December 01, 1999
Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nat Genet (1994) 4.40
Tight junctions and the molecular basis for regulation of paracellular permeability. Am J Physiol (1995) 4.37
A controlled study of adenoviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis. N Engl J Med (1995) 4.30
Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long-term episomal persistence in muscle tissue. J Virol (1998) 4.17
Transfer of genes to humans: early lessons and obstacles to success. Science (1995) 3.64
Liposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Nat Med (1995) 3.61
Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis. Cell (1993) 3.47
Limited entry of adenovirus vectors into well-differentiated airway epithelium is responsible for inefficient gene transfer. J Virol (1998) 3.25
Basolateral localization of fiber receptors limits adenovirus infection from the apical surface of airway epithelia. J Biol Chem (1999) 3.04
Efficient transduction of nondividing human cells by feline immunodeficiency virus lentiviral vectors. Nat Med (1998) 2.58
Molecular structure and assembly of the tight junction. Am J Physiol (1998) 2.35
Adenoviruses as gene-delivery vehicles. N Engl J Med (1996) 2.20
A phase I study of an adeno-associated virus-CFTR gene vector in adult CF patients with mild lung disease. Hum Gene Ther (1996) 1.80
Minimum requirements for efficient transduction of dividing and nondividing cells by feline immunodeficiency virus vectors. J Virol (1999) 1.58
Airway epithelial CFTR mRNA expression in cystic fibrosis patients after repetitive administration of a recombinant adenovirus. J Clin Invest (1999) 1.56
Efficient and persistent gene transfer of AAV-CFTR in maxillary sinus. Lancet (1998) 1.48
Feline immunodeficiency virus vectors persistently transduce nondividing airway epithelia and correct the cystic fibrosis defect. J Clin Invest (1999) 1.46
Lentiviral vectors for gene therapy of cystic fibrosis. Hum Gene Ther (1997) 1.38
A placebo-controlled study of liposome-mediated gene transfer to the nasal epithelium of patients with cystic fibrosis. Gene Ther (1997) 1.11
Aerosol administration of a recombinant adenovirus expressing CFTR to cystic fibrosis patients: a phase I clinical trial. Hum Gene Ther (1997) 1.02
Feline immunodeficiency virus infection: an overview. Vet J (1998) 0.90
Transient permeabilization of airway epithelium by mucosal water. J Appl Physiol (1985) (1996) 0.85
Gene therapy for the respiratory manifestations of cystic fibrosis. Am J Respir Crit Care Med (1995) 0.78
Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med (2001) 9.53
Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution. J Appl Physiol (1985) (1986) 6.86
Inflammatory and immune processes in the human lung in health and disease: evaluation by bronchoalveolar lavage. Am J Pathol (1979) 5.94
Altered chloride ion channel kinetics associated with the delta F508 cystic fibrosis mutation. Nature (1992) 5.45
Idiopathic pulmonary fibrosis. Clinical, histologic, radiographic, physiologic, scintigraphic, cytologic, and biochemical aspects. Ann Intern Med (1976) 4.85
Analysis of cellular and protein content of broncho-alveolar lavage fluid from patients with idiopathic pulmonary fibrosis and chronic hypersensitivity pneumonitis. J Clin Invest (1977) 4.21
Pulmonary sarcoidosis: a disorder mediated by excess helper T-lymphocyte activity at sites of disease activity. N Engl J Med (1981) 4.02
Interstitial lung diseases of unknown cause. Disorders characterized by chronic inflammation of the lower respiratory tract (first of two parts). N Engl J Med (1984) 3.73
Normal alveolar epithelial lining fluid contains high levels of glutathione. J Appl Physiol (1985) (1987) 3.51
Gamma interferon is spontaneously released by alveolar macrophages and lung T lymphocytes in patients with pulmonary sarcoidosis. J Clin Invest (1985) 3.40
Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells. J Exp Med (2001) 3.25
Genetic basis of variable exon 9 skipping in cystic fibrosis transmembrane conductance regulator mRNA. Nat Genet (1993) 3.22
Interstitial lung disease: current concepts of pathogenesis, staging and therapy. Am J Med (1981) 3.08
Systemic glutathione deficiency in symptom-free HIV-seropositive individuals. Lancet (1989) 3.01
Plasma elevation of stromal cell-derived factor-1 induces mobilization of mature and immature hematopoietic progenitor and stem cells. Blood (2001) 3.01
Activated human monocytes express the c-sis proto-oncogene and release a mediator showing PDGF-like activity. Nature (1986) 2.94
Replacement therapy for alpha 1-antitrypsin deficiency associated with emphysema. N Engl J Med (1987) 2.81
Lung overexpression of the vascular endothelial growth factor gene induces pulmonary edema. Am J Respir Cell Mol Biol (2000) 2.81
Spontaneous release of interleukin-2 by lung T lymphocytes in active pulmonary sarcoidosis. N Engl J Med (1983) 2.71
Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Hum Gene Ther (1997) 2.62
Exaggerated spontaneous release of platelet-derived growth factor by alveolar macrophages from patients with idiopathic pulmonary fibrosis. N Engl J Med (1987) 2.62
Neutrophil elastase in respiratory epithelial lining fluid of individuals with cystic fibrosis induces interleukin-8 gene expression in a human bronchial epithelial cell line. J Clin Invest (1992) 2.62
A preliminary study of aerosolized recombinant human deoxyribonuclease I in the treatment of cystic fibrosis. N Engl J Med (1992) 2.57
Evaluation of clinical parameters to predict Mycobacterium tuberculosis in inpatients. Arch Intern Med (2000) 2.46
Gene therapy strategies for tumor antiangiogenesis. J Natl Cancer Inst (1998) 2.44
Molecular basis of alpha-1-antitrypsin deficiency. Am J Med (1988) 2.40
Bronchoalveolar lavage in interstitial lung disease. Ann Intern Med (1978) 2.36
Production of fibronectin by the human alveolar macrophage: mechanism for the recruitment of fibroblasts to sites of tissue injury in interstitial lung diseases. Proc Natl Acad Sci U S A (1981) 2.34
Human alveolar macrophage growth factor for fibroblasts. Regulation and partial characterization. J Clin Invest (1982) 2.33
Modulation of airway inflammation in cystic fibrosis. In vivo suppression of interleukin-8 levels on the respiratory epithelial surface by aerosolization of recombinant secretory leukoprotease inhibitor. J Clin Invest (1992) 2.33
Interstitial lung diseases of unknown cause. Disorders characterized by chronic inflammation of the lower respiratory tract. N Engl J Med (1984) 2.30
Human type III collagen gene expression is coordinately modulated with the type I collagen genes during fibroblast growth. Biochemistry (1986) 2.28
Mechanisms of pulmonary fibrosis. Spontaneous release of the alveolar macrophage-derived growth factor in the interstitial lung disorders. J Clin Invest (1983) 2.27
Fluorescent virions: dynamic tracking of the pathway of adenoviral gene transfer vectors in living cells. Hum Gene Ther (1998) 2.27
Protease-antiprotease imbalance in the lungs of children with cystic fibrosis. Am J Respir Crit Care Med (1994) 2.26
Interleukin-8 gene expression in human bronchial epithelial cells. J Biol Chem (1991) 2.26
Rapid, nonradioactive detection of mutations in the human genome by allele-specific amplification. J Lab Clin Med (1989) 2.22
Cigarette smoking induces functional antiprotease deficiency in the lower respiratory tract of humans. Science (1979) 2.20
Antielastases of the human alveolar structures. Implications for the protease-antiprotease theory of emphysema. J Clin Invest (1981) 2.20
Accurate quantification of cells recovered by bronchoalveolar lavage. Am Rev Respir Dis (1984) 2.17
Collagenase in the lower respiratory tract of patients with idiopathic pulmonary fibrosis. N Engl J Med (1979) 2.13
Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity. J Exp Med (1997) 2.12
Expression of the cystic fibrosis transmembrane conductance regulator gene in the respiratory tract of normal individuals and individuals with cystic fibrosis. Proc Natl Acad Sci U S A (1991) 2.12
Intraluminal fibrosis in interstitial lung disorders. Am J Pathol (1986) 2.10
Mechanisms of neutrophil accumulation in the lungs of patients with idiopathic pulmonary fibrosis. J Clin Invest (1981) 2.10
Maintenance of granuloma formation in pulmonary sarcoidosis by T lymphocytes within the lung. N Engl J Med (1980) 2.07
Aerosol alpha 1-antitrypsin treatment for cystic fibrosis. Lancet (1991) 2.05
Human alveolar macrophage-derived chemotactic factor for neutrophils. Stimuli and partial characterization. J Clin Invest (1980) 2.04
Induction of the hair growth phase in postnatal mice by localized transient expression of Sonic hedgehog. J Clin Invest (1999) 2.02
Dynein- and microtubule-mediated translocation of adenovirus serotype 5 occurs after endosomal lysis. Hum Gene Ther (2000) 1.97
Cigarette smoking and lung destruction. Accumulation of neutrophils in the lungs of cigarette smokers. Am Rev Respir Dis (1983) 1.97
Ultrastructure of pulmonary mast cells in patients with fibrotic lung disorders. Lab Invest (1979) 1.94
Characterization of mononuclear phagocyte subpopulations in the human lung by using monoclonal antibodies: changes in alveolar macrophage phenotype associated with pulmonary sarcoidosis. J Immunol (1985) 1.92
Familial idiopathic pulmonary fibrosis. Evidence of lung inflammation in unaffected family members. N Engl J Med (1986) 1.90
Systemic deficiency of glutathione in cystic fibrosis. J Appl Physiol (1985) (1993) 1.88
Granulocyte collagenase: selective digestion of type I relative to type III collagen. Proc Natl Acad Sci U S A (1977) 1.86
Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation (1999) 1.82
Modulation of alveolar macrophage-driven fibroblast proliferation by alternative macrophage mediators. J Clin Invest (1986) 1.82
Spontaneous expression of the c-sis gene and release of a platelet-derived growth factorlike molecule by human alveolar macrophages. J Clin Invest (1986) 1.80
Neurological deterioration in late infantile neuronal ceroid lipofuscinosis. Neurology (2007) 1.80
Elastin fragments attract macrophage precursors to diseased sites in pulmonary emphysema. Science (1981) 1.80
The alveolitis of pulmonary sarcoidosis. Evaluation of natural history and alveolitis-dependent changes in lung function. Am Rev Respir Dis (1983) 1.76
Localization of the immune response in sarcoidosis. Am Rev Respir Dis (1979) 1.74
Control of collagen production by human diploid lung fibroblasts. J Biol Chem (1980) 1.72
Alveolitis: the key to the interstitial lung disorders. Thorax (1982) 1.71
"Sero-switch" adenovirus-mediated in vivo gene transfer: circumvention of anti-adenovirus humoral immune defenses against repeat adenovirus vector administration by changing the adenovirus serotype. Hum Gene Ther (1996) 1.70
The cystic fibrosis gene has a "housekeeping"-type promoter and is expressed at low levels in cells of epithelial origin. J Biol Chem (1991) 1.70
Adenovirus serotype 7 retention in a late endosomal compartment prior to cytosol escape is modulated by fiber protein. J Virol (2001) 1.70
Alveolar macrophage replication. One mechanism for the expansion of the mononuclear phagocyte population in the chronically inflamed lung. J Clin Invest (1984) 1.68
Bleomycin-induced interstitial pulmonary disease in the nude, athymic mouse. Am Rev Respir Dis (1979) 1.67
Mobilization of endothelial and hematopoietic stem and progenitor cells by adenovector-mediated elevation of serum levels of SDF-1, VEGF, and angiopoietin-1. Ann N Y Acad Sci (2001) 1.67
Oxidant-mediated epithelial cell injury in idiopathic pulmonary fibrosis. J Clin Invest (1987) 1.64
Pathogenesis of the granulomatous lung diseases. Am Rev Respir Dis (1984) 1.64
Role of fibronectin as a growth factor for fibroblasts. J Cell Biol (1983) 1.64
Glutathione deficiency in the epithelial lining fluid of the lower respiratory tract in idiopathic pulmonary fibrosis. Am Rev Respir Dis (1989) 1.64
Adenovirus-mediated transfer of a recombinant human alpha 1-antitrypsin cDNA to human endothelial cells. Proc Natl Acad Sci U S A (1992) 1.62
Direct in vivo gene transfer to ependymal cells in the central nervous system using recombinant adenovirus vectors. Nat Genet (1993) 1.62
The connective tissue of lung. Am Rev Respir Dis (1975) 1.62
Normal human alveolar macrophages obtained by bronchoalveolar lavage have a limited capacity to release interleukin-1. J Clin Invest (1984) 1.61
Variability of human systemic humoral immune responses to adenovirus gene transfer vectors administered to different organs. J Virol (1999) 1.61
Identification of a second mutation in the protein-coding sequence of the Z type alpha 1-antitrypsin gene. J Biol Chem (1986) 1.60
Fiber swap between adenovirus subgroups B and C alters intracellular trafficking of adenovirus gene transfer vectors. J Virol (1999) 1.59
Circumvention of anti-adenovirus neutralizing immunity by administration of an adenoviral vector of an alternate serotype. Hum Gene Ther (1997) 1.59
Z-type alpha 1-antitrypsin is less competent than M1-type alpha 1-antitrypsin as an inhibitor of neutrophil elastase. J Clin Invest (1987) 1.59
Maintenance of alveolitis in patients with chronic beryllium disease by beryllium-specific helper T cells. N Engl J Med (1989) 1.59
Clinical features and history of the destructive lung disease associated with alpha-1-antitrypsin deficiency of adults with pulmonary symptoms. Am Rev Respir Dis (1988) 1.58
Characterization of the lower respiratory tract inflammation of nonsmoking individuals with interstitial lung disease associated with chronic inhalation of inorganic dusts. Am Rev Respir Dis (1987) 1.57
Airway epithelial CFTR mRNA expression in cystic fibrosis patients after repetitive administration of a recombinant adenovirus. J Clin Invest (1999) 1.56
Enhancement of in vivo adenovirus-mediated gene transfer and expression by prior depletion of tissue macrophages in the target organ. J Virol (1997) 1.56
Effect of intermittent high dose parenteral corticosteroids on the alveolitis of idiopathic pulmonary fibrosis. Am Rev Respir Dis (1983) 1.56
Severe deficiency of cystic fibrosis transmembrane conductance regulator messenger RNA carrying nonsense mutations R553X and W1316X in respiratory epithelial cells of patients with cystic fibrosis. J Clin Invest (1991) 1.56
Lung collagen composition and synthesis. Characterization and changes with age. J Biol Chem (1974) 1.56
Construction and characterization of hexon-chimeric adenoviruses: specification of adenovirus serotype. J Virol (1998) 1.55
CAR-dependent and CAR-independent pathways of adenovirus vector-mediated gene transfer and expression in human fibroblasts. J Clin Invest (1999) 1.55
Enhanced alveolar macrophage-mediated antigen-induced T-lymphocyte proliferation in sarcoidosis. J Clin Invest (1985) 1.54
The alpha 1-antitrypsin gene and its deficiency states. Trends Genet (1989) 1.54
Isolation and characterization of a 15-kilobase genomic sequence coding for part of the Pro alpha 2 chain of sheep type I collagen. J Biol Chem (1980) 1.53
Expression of the cystic fibrosis transmembrane conductance regulator gene in cells of non-epithelial origin. Nucleic Acids Res (1991) 1.52
Degradation of newly synthesized collagen. J Biol Chem (1978) 1.52
Use of a highly purified alpha 1-antitrypsin standard to establish ranges for the common normal and deficient alpha 1-antitrypsin phenotypes. Chest (1991) 1.51